• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Rhythm Pharmaceuticals Inc.

    8/7/24 6:03:22 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RYTM alert in real time by email
    DEFA14A 1 tm2419956d3_defa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

     

    SCHEDULE 14A

    (Rule 14a-101)

     

    INFORMATION REQUIRED IN PROXY STATEMENT

    SCHEDULE 14A INFORMATION

     

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. 1)

     

     

     

    Filed by the Registrant  x                             Filed by a Party other than the Registrant  ¨

     

    Check the appropriate box:

     

    ¨ Preliminary Proxy Statement
       
    ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
       
    ¨ Definitive Proxy Statement
       
    x Definitive Additional Materials
       
    ¨ Soliciting Material under §240.14a-12

     

    Rhythm Pharmaceuticals, Inc.

    (Name of Registrant as Specified in its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    x No fee required.
       
    ¨ Fee paid previously with preliminary materials.
       
    ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

    GRAPHIC

    www.investorvote.com/RYTM-AM Step 1: Go to www.investorvote.com/RYTM-AM Step 2: Click on the icon on the right to view meeting materials. Step 3: Return to the investorvote.com window and follow the instructions on the screen to log in. Online - Before the Meeting Go to www.investorvote.com/RYTM-AM or scan the QR code — login details are located in the shaded bar below. Stockholder Meeting Notice 040W1C + + Important Notice Regarding the Availability of Proxy Materials for the Rhythm Pharmaceuticals, Inc. Stockholder Meeting to be Held on September 18, 2024 Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual stockholders’ meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The 2024 Notice and Proxy Statement and 2023 Annual Report are available at: Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before September 8, 2024 to facilitate timely delivery. 2NOT Easy Online Access — View your proxy materials and vote. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. Online - During the Meeting Go to meetnow.global/MR5F5MC. To access the virtual meeting, you must have the information that is printed in the shaded bar located below. Step 4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares.

    GRAPHIC

    Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. — Internet – Go to www.investorvote.com/RYTM-AM. — Phone – Call us free of charge at 1-866-641-4276. — Email – Send an email to [email protected] with “Proxy Materials Rhythm Pharmaceuticals, Inc.” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, requests for a paper copy of proxy materials must be received by September 8, 2024. Rhythm Pharmaceuticals, Inc.’s Annual Meeting of Stockholders will be held on September 18, 2024, at 2:00 PM Eastern Time. The Annual Meeting will be a completely virtual meeting, which will be conducted via live webcast. To access the virtual meeting, you must have the information that is printed in the shaded bar located on the reverse side of this form. Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations. The Board of Directors recommend a vote FOR all the nominees listed in Proposal 1 and FOR Proposals 2, 3 and 4: 1. Election of the Class I directors, each to serve for a three year term until the 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. Nominees 01 - Stuart A. Arbuckle 02 – Christophe R. Jean 03 – Lynn A. Tetrault 2. Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2024. 3. Approval, on an advisory (non-binding) basis, of the compensation of the named executive officers of the Company. 4. Reapproval of the Rhythm Pharmaceuticals, Inc. 2017 Equity Incentive Plan. PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. Stockholder Meeting Notice

    Get the next $RYTM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RYTM

    DatePrice TargetRatingAnalyst
    11/25/2025$136.00Buy
    Citigroup
    11/5/2025Outperform → Perform
    Oppenheimer
    7/14/2025$130.00Mkt Perform → Mkt Outperform
    Citizens JMP
    7/10/2025$97.00Buy
    Goldman
    7/7/2025$88.00Outperform
    Leerink Partners
    4/7/2025$63.00Neutral → Buy
    BofA Securities
    3/5/2025$78.00Buy
    Stifel
    1/2/2025$80.00Buy
    Jefferies
    More analyst ratings

    $RYTM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit

    BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that Hunter C. Smith, Chief Financial Officer, will participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 conference on Wednesday, February 11 at 11:00 a.m. ET in New York. The fireside chat will be webcasted and available under "Events & Presentations" in the Investor Relations section of the Company's website at www.rhythmtx.com. A replay of the webcast will be available on the Rhythm website for 30 days fol

    2/5/26 8:00:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones

    -- Q4 2025 preliminary net product revenues from global sales of IMCIVREE® (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an 11% increase over Q3 2025 -- -- FY 2025 preliminary net product revenue of approximately $194 million, approximately 50% increase from FY2024 -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity -- -- On track to report topline data from 12-patient Japanese cohort of setmelanotide Phase 3 trial in acquired hypothalamic obesity in first quarter of 2026 -- -- On track to report topline data from Phase 3 EMANATE trial evaluating setmelanotide in genetically caused MC4R pathway diseases in first

    1/9/26 8:00:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome

    -- BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled patients remain on therapy -- -- Promising results supportive of Phase 3, registrational trial of setmelanotide in PWS -- -- Company initiated Phase 1, Part D study to evaluate weekly MC4R agonist RM-718 in patients with PWS -- -- Company to hold conference call on Thursday, December 11 at 8:00 a.m. -- BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today

    12/11/25 7:30:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RYTM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Smith Hunter C sold $702,744 worth of shares (6,628 units at $106.03), decreasing direct ownership by 5% to 125,537 units (SEC Form 4)

    4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)

    2/6/26 6:38:19 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Head of International Mazabraud Yann converted options into 5,500 shares, increasing direct ownership by 15% to 43,155 units (SEC Form 4)

    4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)

    2/3/26 4:38:11 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Smith Hunter C converted options into 26,000 shares and covered exercise/tax liability with 10,750 shares, increasing direct ownership by 13% to 132,165 units (SEC Form 4)

    4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)

    2/3/26 4:36:15 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RYTM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Rhythm Pharmaceuticals with a new price target

    Citigroup initiated coverage of Rhythm Pharmaceuticals with a rating of Buy and set a new price target of $136.00

    11/25/25 8:45:08 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rhythm Pharmaceuticals downgraded by Oppenheimer

    Oppenheimer downgraded Rhythm Pharmaceuticals from Outperform to Perform

    11/5/25 7:28:21 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rhythm Pharmaceuticals upgraded by Citizens JMP with a new price target

    Citizens JMP upgraded Rhythm Pharmaceuticals from Mkt Perform to Mkt Outperform and set a new price target of $130.00

    7/14/25 8:28:35 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RYTM
    SEC Filings

    View All

    SEC Form 144 filed by Rhythm Pharmaceuticals Inc.

    144 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

    2/5/26 4:30:28 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Rhythm Pharmaceuticals Inc.

    144 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

    2/4/26 4:21:05 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Rhythm Pharmaceuticals Inc.

    SCHEDULE 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

    1/30/26 2:43:31 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RYTM
    Leadership Updates

    Live Leadership Updates

    View All

    Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer

    BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair "Al" Garfield, Ph.D. as Chief Scientific Officer, effective July 1. "We are excited to welcome Al back to Rhythm as we continue to leverage our understanding of the melanocortin-4 receptor (MC4R) pathway to bring potential therapies to patients and their families," said David Meeker, M.D., Rhythm Chairman, Chief Executive Officer and President. "Al's leadership and established scientific expertise and experience

    7/8/24 8:00:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development

    BOSTON, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced the appointment of Dana Washburn, M.D., as Senior Vice President of Clinical Development and as a member of the Company's Executive Leadership Team, effective September 26, 2022. As SVP of Clinical Development, Dr. Washburn will lead the Company's robust clinical development program, clinical operations, and data management. "Dr. Washburn is a collaborative, resourceful leade

    10/6/22 4:02:00 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wren Appoints Bart Henderson as Chief Executive Officer

    Wren Therapeutics, a biopharmaceutical company transforming drug discovery for neurodegenerative diseases, today announced the appointment of Bart Henderson as Chief Executive Officer. Wren's unique drug discovery platform harnesses advances in the biophysics of protein assembly dynamics to target the toxic fleeting protein intermediates, the oligomers, in neurodegenerative disease pathways, and discover small molecules that can block their generation with precision. Bart brings broad leadership experience in the biotechnology industry as a founder and co-founder of several companies including Torque (now Repertoire Immune Medicines), Rhythm (NASDAQ:RYTM) and its subsidiary Motus (acquired

    3/4/22 8:00:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RYTM
    Financials

    Live finance-specific insights

    View All

    Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome

    -- BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled patients remain on therapy -- -- Promising results supportive of Phase 3, registrational trial of setmelanotide in PWS -- -- Company initiated Phase 1, Part D study to evaluate weekly MC4R agonist RM-718 in patients with PWS -- -- Company to hold conference call on Thursday, December 11 at 8:00 a.m. -- BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today

    12/11/25 7:30:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome

    BOSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast on Thursday, December 11 at 8:00 a.m. ET to disclose preliminary data from its exploratory Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome (PWS). Conference Call Information Rhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET on Thursday, December 11 to discuss this update. Participants may register for the conference call here. It is recommende

    12/10/25 4:01:00 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

    -- FDA sets updated PDUFA goal date of March 20, 2026 –  -- Company to hold conference today at 8:00 a.m. -- BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended by three months the review period for the supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide) for the treatment of acquired hypothalamic obesity. On Nov. 6, the FDA notified the Company that the Prescription Drug User Fee Act (PDUFA) goal date has been extended fr

    11/7/25 7:30:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RYTM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Rhythm Pharmaceuticals Inc.

    SC 13G - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

    11/14/24 9:50:26 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rhythm Pharmaceuticals Inc.

    SC 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

    11/14/24 5:46:11 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rhythm Pharmaceuticals Inc.

    SC 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

    11/12/24 5:23:38 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care